Really can’t expect a better result than that for the first year of IPO. Strong gross margins offer high likelihood of reaching profit if sales growth continue as expected. I think the range of products launched during the year will underpin strong growth in FY’23. It’s an impressive range and the pace that BIO rolled out it’s distribution channels despite the challenges of COVID and supply chain constraints is even more impressive. Looks like we are all set for a great year ahead. Well done BIO!
Ann: Preliminary Final Report, page-2
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
71.0¢ |
Change
0.030(4.41%) |
Mkt cap ! $155.5M | |||
| Open | High | Low | Value | Volume |
| 69.0¢ | 73.0¢ | 68.0¢ | $385.2K | 542.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 54019 | 70.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 71.0¢ | 15877 | 1 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| BIO (ASX) Chart |